Xeris Biopharma reported break-even quarterly earnings per share against the Zacks Consensus Estimate of $0.01, improving from a loss of $0.06 per share a year prior. This resulted in an earnings surprise of -100%, while the previous quarter saw a surprise of +66.67%. <\/p>\n
For the quarter ended September 2025, Xeris Biopharma reported revenues of $74.38 million, which exceeded the consensus estimate by 0.04%. This was an increase from the previous year’s revenue of $54.27 million.<\/p>\n
Since the start of the year, Xeris Biopharma shares have risen by approximately 191.2%, compared to the S&P 500’s increase of 15.6%. Ahead of this earnings release, estimate revisions for the company were unfavourable, leading to a Zacks Rank #4 (Sell) for the stock. <\/p>\n
The current consensus EPS estimate for the upcoming quarter is $0.05 on revenues of $81.18 million and -$0.01 on $287.18 million for the current fiscal year. Another industry peer, Assertio, expects to report a quarterly loss of $0.08 per share, marking a year-over-year change of -166.7%, with expected revenues of $26.9 million, down 7.9% from the previous year.<\/p>\n
The recent earnings report for Xeris Biopharma presents a mixed signal for us, with a narrow miss on earnings per share but a beat on revenue. The break-even result, against a projection of a one-cent profit, has created uncertainty following the stock’s massive 191% run-up this year. Implied volatility for XERS options is currently elevated, reflecting market anticipation of a significant price move in the coming days.<\/p>\n
For those of us leaning bearish, the earnings miss could be the catalyst that triggers a correction. Historically, after such a massive run-up like the one we’ve seen in 2025, even a minor disappointment can spark significant profit-taking. Purchasing put options with strike prices 5-10% below the current market price could be a way to capitalize on a potential downturn, especially if management guidance on the earnings call is cautious.<\/p>\n
On the other hand, the strong 37% year-over-year revenue growth provides a compelling bullish counter-argument. This top-line strength suggests solid underlying demand for the company’s products, which could overshadow the minor earnings miss. Selling cash-secured puts is an attractive strategy to collect premium from the heightened volatility, based on the view that strong sales will limit any significant drop in the stock price.<\/p>\n
Given the binary nature of the upcoming management commentary, a non-directional strategy is also warranted. We saw a similar setup with Assertio (ASRT) back in its Q1 2025 report, where the stock moved over 15% after its earnings call. Implementing a long straddle, which involves buying both a call and a put option, would allow a trader to profit from a large price swing in either direction following the call.<\/p>\n","protected":false},"excerpt":{"rendered":"
Xeris Biopharma posts break-even EPS, beats revenue estimates; shares up 191% year-to-date despite negative revisions.<\/p>\n","protected":false},"author":62,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[59],"tags":[],"class_list":["post-34229","post","type-post","status-publish","format-standard","hentry","category-live-updates"],"acf":{"acf_article_selection_author":null},"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\n\t\t